Skip to main content
Top
Published in: Annals of Surgical Oncology 11/2013

01-10-2013 | Gastrointestinal Oncology

Predicting Postoperative Morbidity Following Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (CS+HIPEC) with Preoperative FACT-C (Functional Assessment of Cancer Therapy) and Patient-Rated Performance Status

Authors: Chukwuemeka U. Ihemelandu, MD, FACS, Richard McQuellon, PhD, Perry Shen, MD, FACS, John H. Stewart, MD, FACS, Konstantinos Votanopoulos, MD, FACS, Edward A. Levine, MD, FACS

Published in: Annals of Surgical Oncology | Issue 11/2013

Login to get access

Abstract

Background

Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CS+HIPEC) is associated with significant perioperative morbidity. One goal of our ongoing patient-reported health-related quality of life (HRQoL) program is to describe the prognostic value of HRQoL measures for predicting postoperative morbidity and mortality following CS+HIPEC.

Methods

A retrospective analysis of a prospectively collected clinical database for all patients treated for peritoneal carcinomatosis and who participated in our patient-reported HRQoL program from 2001 to 2011 was done. Patients completed the Functional Assessment of Cancer Therapy questionnaire plus the colon symptom subscale, in addition to the Eastern Cooperative Oncology Group (ECOG) performance status rating prior to CS+HIPEC. The trial outcome index (TOI), a specific measure of function, symptoms, and physical well being of the patient, was analyzed. The TOI is a combination of the physical and functional well being subscales + the colon-specific subscale of the FACT-C.

Results

Of 855 patients, 387 (45.2 %) participated in the HRQoL trials. Mean age was 53.3 years, and 213 (55 %) were female versus 174 (45 %) males. There were 240 patients (62 %) who had a complication versus 147 (38 %) who had no complication. A 30-day mortality rate of 7.7 % (30) was documented. Patients who suffered a 30-day postoperative mortality demonstrated a lower mean preoperative score in the FACT-C TOI 52.7 versus 61.7; P < 0.001. Independent predictors of 30-day mortality on multivariate analysis included TOI (0.05), age (0.001), and smoking (0.001). Patients with a higher TOI score were less likely to suffer a mortality (95 % CI 0.9–1.0, P = 0.05). Patients with a higher emotional well being (EWB) score were less likely to suffer a complication 0.9 (95 % CI 0.87–1.0, P = 0.04). Other independent predictors of postoperative morbidity included diabetic status (P = 0.05), ECOG performance status (0.001), and gender (0.02).

Conclusions

Preoperative HRQoL, as measured by FACT-C and ECOG performance status and added to traditional factors, helps predict postoperative morbidity and mortality following CS+HIPEC.
Literature
1.
go back to reference Stewart JH 4th, Shen P, Russell GB, Bradley RF, Hundley JC, Loggie BL, et al. Appendiceal neoplasms with peritoneal dissemination: outcomes after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy. Ann Surg Oncol. 2006;13:624–34.PubMedCrossRef Stewart JH 4th, Shen P, Russell GB, Bradley RF, Hundley JC, Loggie BL, et al. Appendiceal neoplasms with peritoneal dissemination: outcomes after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy. Ann Surg Oncol. 2006;13:624–34.PubMedCrossRef
2.
go back to reference Glehen O, Osinsky D, Cotte E, Kwiatkowski F, Freyer G, Isaac S, et al. Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol. 2003;10:863–9.PubMedCrossRef Glehen O, Osinsky D, Cotte E, Kwiatkowski F, Freyer G, Isaac S, et al. Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol. 2003;10:863–9.PubMedCrossRef
3.
go back to reference Sugarbaker PH, Alderman R, Edwards G, Marquardt CE, Gushchin V, Esquivel J, et al. Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy. Ann Surg Oncol. 2006;13:635–44.PubMedCrossRef Sugarbaker PH, Alderman R, Edwards G, Marquardt CE, Gushchin V, Esquivel J, et al. Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy. Ann Surg Oncol. 2006;13:635–44.PubMedCrossRef
4.
go back to reference Shen P, Hawksworth J, Lovato J, Loggie BW, Geisinger KR, Fleming RA, et al. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. Ann Surg Oncol. 2004;11:178–86.PubMedCrossRef Shen P, Hawksworth J, Lovato J, Loggie BW, Geisinger KR, Fleming RA, et al. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. Ann Surg Oncol. 2004;11:178–86.PubMedCrossRef
5.
go back to reference Smeenk RM, Verwaal VJ, Zoetmulder FA. Toxicity and mortality of cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei—a report of 103 procedures. Eur J Surg Oncol. 2006;32:186–90.PubMedCrossRef Smeenk RM, Verwaal VJ, Zoetmulder FA. Toxicity and mortality of cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei—a report of 103 procedures. Eur J Surg Oncol. 2006;32:186–90.PubMedCrossRef
6.
go back to reference Kusamura S, Younan R, Baratti D, Costanzo P, Favaro M, Gavazzi C, et al. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique. Cancer. 2006;106:1144–53.PubMedCrossRef Kusamura S, Younan R, Baratti D, Costanzo P, Favaro M, Gavazzi C, et al. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique. Cancer. 2006;106:1144–53.PubMedCrossRef
7.
go back to reference Jones J, de Cossart L. Risk scoring in surgical patients. Br J Surg. 2003;86:149–57.CrossRef Jones J, de Cossart L. Risk scoring in surgical patients. Br J Surg. 2003;86:149–57.CrossRef
8.
go back to reference Wakabayashi H, Sano T, Yachida S, Okano K, Izuishi K, Suzuki Y. Validation of risk assessment scoring systems for an audit of elective surgery for gastrointestinal cancer in elderly patients: an audit. Int J Surg. 2007;5:323–7.PubMedCrossRef Wakabayashi H, Sano T, Yachida S, Okano K, Izuishi K, Suzuki Y. Validation of risk assessment scoring systems for an audit of elective surgery for gastrointestinal cancer in elderly patients: an audit. Int J Surg. 2007;5:323–7.PubMedCrossRef
9.
go back to reference Velanovich V. Preoperative laboratory screening based on age, gender, and concomitant medical diseases. Surgery. 1994;115:56–61.PubMed Velanovich V. Preoperative laboratory screening based on age, gender, and concomitant medical diseases. Surgery. 1994;115:56–61.PubMed
10.
go back to reference Velanovich V. The value of routine preoperative laboratory testing in predicting postoperative complications: a multivariate analysis. Surgery. 1991;109:236–43.PubMed Velanovich V. The value of routine preoperative laboratory testing in predicting postoperative complications: a multivariate analysis. Surgery. 1991;109:236–43.PubMed
11.
go back to reference Holloway S, Sarosi G, Kim L, Nwariaku F, O’Keefe G, Hynan L, et al. Health-related quality of life and postoperative length of stay for patients with colorectal cancer. J Surg Res. 2002;108:273–8.PubMedCrossRef Holloway S, Sarosi G, Kim L, Nwariaku F, O’Keefe G, Hynan L, et al. Health-related quality of life and postoperative length of stay for patients with colorectal cancer. J Surg Res. 2002;108:273–8.PubMedCrossRef
12.
go back to reference Fang FM, Chien CY, Tsai WL, Chen HC, Hsu HC, Lui CC, et al. Quality of life and survival outcome for patients with nasopharyngeal carcinoma receiving three-dimensional conformal radiotherapy vs. intensity-modulated radiotherapy: A longitudinal study. Int J Radiat Oncol Biol Phys. 2008;72:356–64.PubMedCrossRef Fang FM, Chien CY, Tsai WL, Chen HC, Hsu HC, Lui CC, et al. Quality of life and survival outcome for patients with nasopharyngeal carcinoma receiving three-dimensional conformal radiotherapy vs. intensity-modulated radiotherapy: A longitudinal study. Int J Radiat Oncol Biol Phys. 2008;72:356–64.PubMedCrossRef
13.
go back to reference Conroy T, Bleiberg H, Glimelius B. Quality of life in patients with advanced colorectal cancer: what has been learnt? Eur J Cancer. 2003;39:287–94.PubMedCrossRef Conroy T, Bleiberg H, Glimelius B. Quality of life in patients with advanced colorectal cancer: what has been learnt? Eur J Cancer. 2003;39:287–94.PubMedCrossRef
14.
go back to reference Maisey NR, Norman A, Watson M, Allen MJ, Hill ME, Cunningham D. Baseline quality of life predicts survival in patients with advanced colorectal cancer. Eur J Cancer. 2002;38:1351–7.PubMedCrossRef Maisey NR, Norman A, Watson M, Allen MJ, Hill ME, Cunningham D. Baseline quality of life predicts survival in patients with advanced colorectal cancer. Eur J Cancer. 2002;38:1351–7.PubMedCrossRef
15.
go back to reference Earlam S, Glover C, Fordy C, Burke D, Allen-Mersh TG. Relation between tumor size, quality of life, and survival in patients with colorectal liver metastases. J Clin Oncol. 1996;14:171–5.PubMed Earlam S, Glover C, Fordy C, Burke D, Allen-Mersh TG. Relation between tumor size, quality of life, and survival in patients with colorectal liver metastases. J Clin Oncol. 1996;14:171–5.PubMed
16.
go back to reference Saxton A, Velanovich V. Preoperative frailty and quality of life as predictors of postoperative complications. Ann Surg. 2011;253:1223–9.PubMedCrossRef Saxton A, Velanovich V. Preoperative frailty and quality of life as predictors of postoperative complications. Ann Surg. 2011;253:1223–9.PubMedCrossRef
17.
go back to reference Anthony T, Hynan LS, Rosen D, Kim L, Nwariaku F, Jones C, et al. The association of pretreatment health-related quality of life with surgical complications for patients undergoing open surgical resection for colorectal cancer. Ann Surg. 2003;238:690–6.PubMedCrossRef Anthony T, Hynan LS, Rosen D, Kim L, Nwariaku F, Jones C, et al. The association of pretreatment health-related quality of life with surgical complications for patients undergoing open surgical resection for colorectal cancer. Ann Surg. 2003;238:690–6.PubMedCrossRef
18.
go back to reference Ward WL, Hahn EA, Mo F, Hernandez L, Tulsky DS, Cella D, et al. Reliability and validity of the functional assessment of cancer therapy-colorectal(FACT-C) HRQOL instrument. Qual Life Res. 1999;8:181–95.PubMedCrossRef Ward WL, Hahn EA, Mo F, Hernandez L, Tulsky DS, Cella D, et al. Reliability and validity of the functional assessment of cancer therapy-colorectal(FACT-C) HRQOL instrument. Qual Life Res. 1999;8:181–95.PubMedCrossRef
19.
go back to reference Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11:570–9.PubMed Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11:570–9.PubMed
20.
go back to reference Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982:5:649–55.PubMedCrossRef Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982:5:649–55.PubMedCrossRef
21.
go back to reference Dindo D, Demartines N, Clavien P-A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.PubMedCrossRef Dindo D, Demartines N, Clavien P-A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.PubMedCrossRef
22.
go back to reference Cavaliere F, Valle M, De Simone M, Deraco M, Rossi CR, Di Filippo F, et al. 120 peritoneal carcinomatoses from colorectal cancer treated with peritonectomy and intra-abdominal chemohyperthermia: a S.I.T.I.L.O. multicentric study. In Vivo. 2006;20:747–50.PubMed Cavaliere F, Valle M, De Simone M, Deraco M, Rossi CR, Di Filippo F, et al. 120 peritoneal carcinomatoses from colorectal cancer treated with peritonectomy and intra-abdominal chemohyperthermia: a S.I.T.I.L.O. multicentric study. In Vivo. 2006;20:747–50.PubMed
23.
go back to reference Zanon C, Bortolini M, Chiappino I, Simone P, Bruno F, Gaglia P, et al. Cytoreductive surgery combined with intraperitoneal chemohyperthermia for the treatment of advanced colon cancer. World J Surg. 2006;30:2025–32.PubMedCrossRef Zanon C, Bortolini M, Chiappino I, Simone P, Bruno F, Gaglia P, et al. Cytoreductive surgery combined with intraperitoneal chemohyperthermia for the treatment of advanced colon cancer. World J Surg. 2006;30:2025–32.PubMedCrossRef
24.
go back to reference Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22:3284–92.PubMedCrossRef Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22:3284–92.PubMedCrossRef
25.
go back to reference Ford MK, Beattie WS, Wifeysundera DN. Systematic review: prediction of perioperative cardiac complications and mortality by the revised cardiac risk index. Ann Intern Med. 2010;152:26–35.PubMedCrossRef Ford MK, Beattie WS, Wifeysundera DN. Systematic review: prediction of perioperative cardiac complications and mortality by the revised cardiac risk index. Ann Intern Med. 2010;152:26–35.PubMedCrossRef
26.
go back to reference Bapoje SR, Whitaker JF, Schulz T, Chu ES, Albert RK, et al. Preoperative evaluation of the patient with pulmonary disease. Chest. 2007;132:1637–45.PubMedCrossRef Bapoje SR, Whitaker JF, Schulz T, Chu ES, Albert RK, et al. Preoperative evaluation of the patient with pulmonary disease. Chest. 2007;132:1637–45.PubMedCrossRef
27.
go back to reference Caprini JA. Risk assessment as a guide for the prevention of the many faces of venous thromboembolism. Am J Surg. 2010;199:S3–S10.PubMedCrossRef Caprini JA. Risk assessment as a guide for the prevention of the many faces of venous thromboembolism. Am J Surg. 2010;199:S3–S10.PubMedCrossRef
28.
go back to reference Eton D, Fairclough D, Cella D, Yount S, Bonomi P, Johnson D. Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: Results from Eastern Cooperative Oncology Group Study 5592. J Clin Oncol. 2003;21:1536–43.PubMedCrossRef Eton D, Fairclough D, Cella D, Yount S, Bonomi P, Johnson D. Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: Results from Eastern Cooperative Oncology Group Study 5592. J Clin Oncol. 2003;21:1536–43.PubMedCrossRef
29.
go back to reference Trask PC, Hsu MA, McQuellon R. Other paradigms: health-related quality of life as a measure in cancer treatment: its importance and relevance. Cancer J 2009;15:435–40.PubMedCrossRef Trask PC, Hsu MA, McQuellon R. Other paradigms: health-related quality of life as a measure in cancer treatment: its importance and relevance. Cancer J 2009;15:435–40.PubMedCrossRef
30.
go back to reference McQuellon R, Duckworth KE. Health-related quality of life and cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy. Curr Probl Cancer. 2009;33:203–18.PubMedCrossRef McQuellon R, Duckworth KE. Health-related quality of life and cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy. Curr Probl Cancer. 2009;33:203–18.PubMedCrossRef
31.
go back to reference Reuter NP, Macgregor JM, Woodall CE, Sticca RP, William C, Helm MB, et al. Preoperative performance status predicts outcome following heated intraperitoneal chemotherapy. Am J Surg. 2008;196:909–13; discussion 913–4. Reuter NP, Macgregor JM, Woodall CE, Sticca RP, William C, Helm MB, et al. Preoperative performance status predicts outcome following heated intraperitoneal chemotherapy. Am J Surg. 2008;196:909–13; discussion 913–4.
32.
go back to reference Ware JE Jr, Kosinski M, Gandek B. SF-36R Health Survey: manual & interpretation guide. Lincoln, RI: QualityMetric Inc., 1993, 2000. Ware JE Jr, Kosinski M, Gandek B. SF-36R Health Survey: manual & interpretation guide. Lincoln, RI: QualityMetric Inc., 1993, 2000.
33.
go back to reference Shen, Levine EA, Hall J, Case D, Russell G, Fleming R, et al. Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. Arch Surg. 2003;138:26–33. Shen, Levine EA, Hall J, Case D, Russell G, Fleming R, et al. Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. Arch Surg. 2003;138:26–33.
34.
go back to reference Deraco M, Nonaka D, Baratti D, Casali P, Rosai J, Younan R, et al. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol. 2006;13:229–37.PubMedCrossRef Deraco M, Nonaka D, Baratti D, Casali P, Rosai J, Younan R, et al. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol. 2006;13:229–37.PubMedCrossRef
35.
go back to reference Esquivel J, Sticca R, Sugarbaker P, Levine E, Yan TD, Alexander R, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Ann Surg Oncol. 2007;14:128–33.PubMed Esquivel J, Sticca R, Sugarbaker P, Levine E, Yan TD, Alexander R, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Ann Surg Oncol. 2007;14:128–33.PubMed
36.
go back to reference Watson M, Haviland JS, Greer S, Davidson J, Bliss JM. Influence of psychological response on survival in breast cancer; a population base cohort study. Lancet. 1999;354:1331–6.PubMedCrossRef Watson M, Haviland JS, Greer S, Davidson J, Bliss JM. Influence of psychological response on survival in breast cancer; a population base cohort study. Lancet. 1999;354:1331–6.PubMedCrossRef
37.
go back to reference Cunningham AJ, Phillips C, Stephen J, Edmonds, C. Fighting for life: A qualitative analysis of the process of psychotherapy-assisted self-help in patients with metastatic cancer. Integr Cancer Ther. 2002;1:146–61.PubMedCrossRef Cunningham AJ, Phillips C, Stephen J, Edmonds, C. Fighting for life: A qualitative analysis of the process of psychotherapy-assisted self-help in patients with metastatic cancer. Integr Cancer Ther. 2002;1:146–61.PubMedCrossRef
Metadata
Title
Predicting Postoperative Morbidity Following Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (CS+HIPEC) with Preoperative FACT-C (Functional Assessment of Cancer Therapy) and Patient-Rated Performance Status
Authors
Chukwuemeka U. Ihemelandu, MD, FACS
Richard McQuellon, PhD
Perry Shen, MD, FACS
John H. Stewart, MD, FACS
Konstantinos Votanopoulos, MD, FACS
Edward A. Levine, MD, FACS
Publication date
01-10-2013
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 11/2013
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-013-3049-8

Other articles of this Issue 11/2013

Annals of Surgical Oncology 11/2013 Go to the issue